Actipulse Neuroscience

Executive Summary

Actipulse Neuroscience is a San Francisco-based nanotechnology company pioneering non-invasive brain stimulation (NIBS) technologies for treating psychiatric and neurological disorders, including Parkinson's disease, depression, anxiety, OCD, ADHD, autism, and vascular brain events. Founded in 2016, the company is currently in Phase 3 development, indicating advanced clinical validation. Its approach leverages nanotechnology to enhance the precision and efficacy of brain stimulation, potentially offering safer and more accessible alternatives to invasive procedures or pharmaceutical interventions. While specific financial details and trial data are not publicly disclosed, the company's progression to late-stage clinical testing suggests growing confidence in its platform. Actipulse's focus on underserved neurological conditions positions it in a high-demand market with significant unmet need, though competition from established neurostimulation players like NeuroPace and Magstim remains. Key risks include scalability of manufacturing, regulatory approval hurdles, and demonstration of superior efficacy in Phase 3 trials.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 trial top-line data readout for lead indication (e.g., depression or Parkinson's)65% success
• Q2 2027FDA submission for breakthrough device designation or premarket approval50% success
• Q3 2026Strategic partnership or licensing deal with a major pharmaceutical or medical device company40% success